Business Context and Reporting Period
This Form 8-K was filed by Tempest Therapeutics, Inc. on July 23, 2021. The report details a corporate event occurring on the same date regarding the establishment of an equity distribution facility.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric disclosed is the authorization of a potential capital raise of up to $100,000,000 in aggregate sales price of common stock.
Material Changes
- Equity Sales Agreement: The Company entered into a Sales Agreement with Jefferies LLC to sell common stock from time to time.
- Offering Structure: Sales may be conducted as "at the market" offerings or negotiated transactions on the Nasdaq Capital Market or other trading venues.
- Compensation: Jefferies LLC is entitled to a commission of 3.0% of the gross proceeds from shares sold.
Guidance, Outlook, and Management Commentary
Management intends to use net proceeds from the offering, if any, to fund the continued development of product candidates in the Company's pipeline, as well as for working capital, capital expenditures, and general corporate purposes. The filing notes that actual sales will depend on market conditions, trading prices, and the Company's capital needs.
Investor Verification Checklist
- Verify the current trading price of TPST on the Nasdaq Capital Market to assess potential dilution.
- Review the attached Sales Agreement (Exhibit 1.1) for specific termination rights and volume limitations.
- Monitor subsequent filings for actual share issuance volumes and proceeds raised under this agreement.
- Confirm the status of the Company's product pipeline development to evaluate the necessity of the capital raise.